Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patientsDivij Mathew, Andy J. Minn, Soyeong Jun et al.|Science|2024Cited by 205
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G. Pfister, Joshua Bauml, Robert I. Haddad et al.|Cancer Medicine|2022Cited by 48
Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)Tanguy Y. Seiwert, Laura Q.M. Chow, Robert I. Haddad et al.|Cancer Research|2018Cited by 38